文献速递肿瘤 PET/CT核素与放射性配体治疗

以人钠碘同向转运体为报告基因的PET成像对靶向HER2卵巢癌的CAR-NK细胞进行显像

Imaging CAR-NK cells targeted to HER2 ovarian cancer with human sodium-iodide symporter-based positron emission tomography.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2024-05-09

本研究将靶向HER2的CAR与PET报告基因人钠碘同向转运体(NIS)共表达于NK-92细胞,在表达萤火虫素酶(Fluc)的HER2卵巢癌小鼠模型中评估其疗效与PET显像能力。CAR-NK细胞较初始NK细胞显著增强细胞毒性,治疗小鼠肿瘤负荷降低、生存延长,[18F]TFB PET信号在表达NIS的CAR-NK细胞治疗小鼠中显著更高。研究表明HER2靶向CAR-NK细胞在侵袭性卵巢癌模型中具有治疗潜力,并证明人源PET报告基因成像无创监测这些细胞的可行性。

要点

  • CAR-NK细胞较初始NK细胞对HER2卵巢癌细胞细胞毒性显著增强。
  • CAR-NK细胞治疗小鼠较对照肿瘤负荷降低、生存延长。
  • [18F]TFB PET在表达NIS的CAR-NK细胞治疗小鼠中信号显著更高。

核心结论

  • 本研究展示HER2靶向CAR-NK细胞在侵袭性卵巢癌模型中的治疗潜力,并强调人源PET报告基因成像无创监测这些细胞在患者中的可行性。

研究设计与样本

  • 将NK-92细胞遗传修饰表达靶向HER2的CAR、生物发光报告基因Antares和NIS,HER2表达卵巢癌细胞表达生物发光报告基因萤火虫素酶(Fluc),在HER2卵巢癌小鼠模型中进行共培养实验和体内研究。

主要发现

  • 共培养实验显示CAR-NK细胞较初始NK细胞细胞毒性显著增强。
  • 在携带Fluc表达肿瘤的小鼠中,CAR-NK细胞治疗组较对照组肿瘤负荷降低、生存延长。
  • 纵向生物发光成像显示CAR-NK细胞信号随时间稳定。
  • 使用NIS靶向示踪剂18F-四氟硼酸盐([18F]TFB)的PET成像显示,表达NIS的CAR-NK细胞治疗小鼠PET信号显著更高。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chimeric antigen receptor (CAR) cell therapies utilize CARs to redirect immune cells towards cancer cells expressing specific antigens like human epidermal growth factor receptor 2 (HER2). Despite their potential, CAR T cell therapies exhibit variable response rates and adverse effects in some patients. Non-invasive molecular imaging can aid in predicting patient outcomes by tracking infused cells post-administration. CAR-T cells are typically autologous, increasing manufacturing complexity and costs. An alternative approach involves developing CAR natural killer (CAR-NK) cells as an off-the-shelf allogeneic product. In this study, we engineered HER2-targeted CAR-NK cells co-expressing the positron emission tomography (PET) reporter gene human sodium-iodide symporter (NIS) and assessed their therapeutic efficacy and PET imaging capability in a HER2 ovarian cancer mouse model.NK-92 cells were genetically modified to express a HER2-targeted CAR, the bioluminescence imaging reporter Antares, and NIS. HER2-expressing ovarian cancer cells were engineered to express the bioluminescence reporter Firefly luciferase (Fluc). Co-culture experiments demonstrated significantly enhanced cytotoxicity of CAR-NK cells compared to naive NK cells. In vivo studies involving mice with Fluc-expressing tumors revealed that those treated with CAR-NK cells exhibited reduced tumor burden and prolonged survival compared to controls. Longitudinal bioluminescence imaging demonstrated stable signals from CAR-NK cells over time. PET imaging using the NIS-targeted tracer 18F-tetrafluoroborate ([18F]TFB) showed significantly higher PET signals in mice treated with NIS-expressing CAR-NK cells.Overall, our study showcases the therapeutic potential of HER2-targeted CAR-NK cells in an aggressive ovarian cancer model and underscores the feasibility of using human-derived PET reporter gene imaging to monitor these cells non-invasively in patients.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Shalaby N, Xia Y, Kelly JJ, et al. Imaging CAR-NK cells targeted to HER2 ovarian cancer with human sodium-iodide symporter-based positron emission tomography. Eur J Nucl Med Mol Imaging. 2024. PMID: 38722382. doi:10.1007/s00259-024-06722-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。